Blue Jet Healthcare opens ₹600 crore QIP to fund CDMO expansion
What's the deal? Blue Jet HealthcareDealroom has a profile for this one. Try Dealroom → has launched a ₹600 crore (roughly $63 million) qualified institutional placement (QIP), priced at an indicative ₹506 per share — a 10% discount to July 6's ₹572 close on the NSE. The specialty pharma and contract development and manufacturing company opened the issue on 6 July 2026, after its finance committee set a floor price of ₹531.70 under SEBI regulations.
Why now? The company secured board approval to raise up to ₹1,000 crore via QIP, preferential allotment or other routes, and shareholders backed the plan at an extraordinary general meeting in June 2026. This is one of Blue Jet's first major primary equity raises: its 2023 IPO of ₹840 crore was entirely an offer-for-sale, adding no fresh capital.
What's the endgame? The proceeds are earmarked for capex, product development, working capital and debt reduction. Blue Jet is also running a ₹1,000+ crore greenfield expansion in Andhra Pradesh, signalling an aggressive push to scale as a global CDMO player.
The numbers behind it: The raise follows a weaker quarter. For the three months to March 2026, net profit fell 41.5% year-on-year to ₹64.3 crore and revenue dropped 31% to ₹235 crore, while EBITDA margin narrowed to 30.3% from 41%.
What could go wrong? Pricing the placement at a discount to market dilutes existing holders, and the timing — right after a sharp earnings decline — tests institutional appetite. Capacity build funded by equity and debt raises execution risk if demand lags.
The signal: Across India's specialty chemicals and pharma intermediates sector, peers have tapped markets for capex-heavy expansions. Blue Jet's QIP is notable because it funds growth directly rather than reshuffling ownership — a shift from balance-sheet-neutral deals toward primary capital for scale.
Read more: CNBC TV18
Image credit: Generated with Gemini
